Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 801–900 of 1,029
Rajalakshmi, R., Rani, C. S. S., Venkatesan, U., Ranjit Unnikrishnan, I., Anjana, R. M., Rani, S. J., UmaSankari, G., Sivaprasad, S., Raman, R., & Mohan, V. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001325 · Cited by 46
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
Global burden and gender disparity of vision loss associated with diabetes retinopathy
Xu, Y., Wang, A., Lin, X., Xu, J., Shan, Y., Pan, X., Ye, J., & Shan, P. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14644 · Cited by 53
“Diabetic retinopathy, the common and specific microvascular complication of diabetes mellitus (DM), remains the leading cause of vision impairment and preventable blindness among the working-age population in many developed nations (Frank 2004; Cheung et al., 2010; Yau et al. 2012).”
BackgroundInfluentialRole of Oxidative Stress and Severity of Diabetic Retinopathy in Type 1 and Type 2 Diabetes
Bokhary, K. A., Aljaser, F., Abudawood, M., Tabassum, H., Bakhsh, A., Alhammad, S., Aleyadhi, R., Almajed, F., & Alsubki, R. A. (2021) · Ophthalmic Research · doi:10.1159/000514722 · Cited by 45
Cai, F., Jiang, H., Li, Y., Li, Q., & Yang, C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.035 · Cited by 47
Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy
Oshitari, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010439 · Cited by 45
Molecular biomarkers in diabetes mellitus (DM)
Zarch, S. M. A., Tezerjani, M. D., Talebi, M., & Mehrjardi, M. Y. V. (2020) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.34.28 · Cited by 55
Nanoparticles for the treatment of ocular neovascularizations
Hennig, R., & Göpferich, A. M. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.027 · Cited by 48
Allingham, M. J., Mukherjee, D., Lally, E. B., Rabbani, H., Mettu, P. S., Cousins, S. W., & Farsiu, S. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.2.7 · Cited by 45
Automated Diagnosis and Grading of Diabetic Retinopathy Using Optical Coherence Tomography
Sandhu, H. S., Eltanboly, A., Shalaby, A., Keynton, R. S., Schaal, S., & El-Baz, A. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-23677 · Cited by 44
“Its microvascular complications are well known, including diabetic retinopathy (DR), from which an estimated 38% of diabetics suffer worldwide.(3) Early detection and treatment of the disease are mainstays of management, and this principle drives the American Academy of Ophthalmology and American Diabetes Society guid…”
BackgroundPericytes: Problems and Promises for CNS Repair
Laredo, F., Plebanski, J., & Tedeschi, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00546 · Cited by 44
“Although only about one-third of diabetic patients develop proliferative, or sight-threatening diabetic retinopathy (Yau et al., 2012), it is still considered the leading cause of blindness globally in working-aged adults (Armulik et al.”
BackgroundКочетова, О. В., Avzaletdinova, D. S., Korytina, G. F., Моругова, Т. В., & Mustafina, O. E. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05304-x · Cited by 45
Human treelike tubular structure segmentation: A comprehensive review and future perspectives
Li, H., Tang, Z., Yang, N., & Yang, G. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106241 · Cited by 54
Hashimoto, Y., Okada, A., Matsui, H., Yasunaga, H., Aihara, M., & Obata, R. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00969-2 · Cited by 46
“4% among patients with DM [35]; thus, the prevalence of DME in the general population would be approximately 1.”
BackgroundCheema, A. A., & Cheema, H. R. (2024) · Cureus · doi:10.7759/cureus.52676 · Cited by 78
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
VEGF −634G>C polymorphism and diabetic retinopathy risk: A meta-analysis
Qiu, M., Xiong, W., Liao, H., & Li, F. (2013) · Gene · doi:10.1016/j.gene.2013.01.018 · Cited by 45
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema
Staurenghi, G., Ye, L., Magee, M. H., Danis, R. P., Wurzelmann, J. I., Adamson, P., & McLaughlin, M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.014 · Cited by 44
Kahtani, E. A., Xu, Z., Rashaed, S. A., Wu, L., Mahale, A., Tian, J., Abboud, E. B., Ghazi, N. G., Kozak, I., Gupta, V., et al. (2016) · Eye · doi:10.1038/eye.2016.246 · Cited by 47
A review of the multifunctionality of angiopoietin-like 4 in eye disease
Yang, X., Cheng, Y., & Su, G. (2018) · Bioscience Reports · doi:10.1042/bsr20180557 · Cited by 44
Lin, K., Hsu, C.-C., Ou, H., Wang, C., Chin, M.-C., & Shin, S.-J. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.027 · Cited by 44
Chung, Y.-R., Ha, K. H., Lee, K., & Kim, D. J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224549 · Cited by 41
Prathiba, V., Rajalakshmi, R., Arulmalar, S., Usha, M., Subhashini, R., Gilbert, C. E., Anjana, R., & Mohan, V. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1937_19 · Cited by 44
Álvarez-Ramos, P., Jiménez, S., Alemany-Marquez, P., Córdoba-Doña, J. A., & Aguilar‐Diosdado, M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001387 · Cited by 46
Alharbi, A. M., & Alhazmi, A. M. S. (2020) · Cureus · doi:10.7759/cureus.11991 · Cited by 51
“6% among diabetic patients globally [6].”
BackgroundYan, X., Han, X., Wu, C., Shang, X., Zhang, L., & He, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0239214 · Cited by 46
“To date, there are about 100 million DR patients worldwide, and one third suffer vision-threatening DR [3].”
BackgroundPenetration Enhancers for Topical Drug Delivery to the Ocular Posterior Segment—A Systematic Review
Thareja, A., Hughes, H., Alvarez-Lorenzo, C., Hakkarainen, J. J., & Ahmed, Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020276 · Cited by 42
Zuo, J., Lan, Y., Hu, H., Hou, X., Li, J., Wang, T., Zhang, H., Zhang, N., Guo, C., Peng, F., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001443 · Cited by 50
Prevalence of diabetic retinopathy in urban and rural India: A systematic review and meta-analysis
Brar, A. S., Sahoo, J., Behera, U. C., Jonas, J. B., Sivaprasad, S., & Das, T. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2206_21 · Cited by 47
“6% among people with diabetes mellitus (DM) in 2012.[1] A recent meta‐analysis (comprising 59 studies) found a lower prevalence estimate of 22.”
BackgroundInfluentialLiu, S., LIN, Y., & LIU, X. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2877 · Cited by 47
“In 2012, there were ~93 million cases of DR globally, 17 million of which were PDR (4).”
Advances in retinal imaging for diabetic retinopathy and diabetic macular edema
Sadda, S., Tan, C. H., Chew, M. C., & Lim, L. W. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.178145 · Cited by 44
A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy
Vujosevic, S., Pucci, P., Casciano, M., Daniele, A., Bini, S., Berton, M., Cavarzeran, F., Avogaro, A., Lapolla, A., & Midena, E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.010 · Cited by 46
Patel, D., Ananthakrishnan, A., Lin, T., Channa, R., Liu, T. Y. A., & Wolf, R. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237120 · Cited by 43
Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
“Chronic retinal diseases (fundus diseases) are rapidly increasing as the lifespan extends in the global population [1, 2].”
BackgroundOwens, D. R., Gurudas, S., Sivaprasad, S., Zaidi, F. H., Tapp, R. J., Kazantzis, D., Evans, L., & Thomas, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112346 · Cited by 50
Telemedicine and ocular health in diabetes mellitus
Bursell, S., Brazionis, L., & Jenkins, A. J. (2012) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2012.00746.x · Cited by 49
A Web-Based Interactive Diabetes Registry for Health Care Management and Planning in Saudi Arabia
Al-Rubeaan, K. A., Youssef, A. M., Subhani, S., Ahmad, N. A., Al‐Sharqawi, A. H., & Ibrahim, H. M. (2013) · Journal of Medical Internet Research · doi:10.2196/jmir.2722 · Cited by 43
Lin, J.-C., Shau, W., & Lai, M. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.859 · Cited by 43
Relationship between Diabetic Retinopathy and Subclinical Hypothyroidism: a meta-analysis
Wu, J., Yue, S., Geng, J., Liu, L., Teng, W., Liu, L., & Chen, L. (2015) · Scientific Reports · doi:10.1038/srep12212 · Cited by 46
Sunita, M., Singh, A. K., Rogye, A., Sonawane, M., Gaonkar, R., Srinivasan, R., Natarajan, S., Stevens, F. C. J., Scherpbier, A. J. J. A., Kumaramanickavel, G., et al. (2017) · Ophthalmic Epidemiology · doi:10.1080/09286586.2017.1290258 · Cited by 43
Astragaloside IV protects RGC-5 cells against oxidative stress
Kuang, H., Hao, M., Liu, Y., Chen, P., & Jiang, H. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.233452 · Cited by 43
“Increased reactive oxygen species (ROS) affect neuronal cells, causing neuronal cell apoptosis and visual impairment (Ozawa et al., 2011; Masuda et al., 2017).”
BackgroundYang, H., Young, D. Y. L., Gao, J., Yuan, Y., Shen, M., Zhang, Y., Duan, X., Zhu, S., & Sun, X. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-0970-2 · Cited by 43
Tan, T., Nguyen, Q., Chua, J., Schmetterer, L. F., Tan, G. S. W., Wong, C. W., Tsai, A. S. H., Cheung, G. C. M., Wong, T. Y., & Ting, D. S. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-47770-9 · Cited by 44
Self-citationUdaondo, P., Hernández, C., Briansó‐Llort, L., Delpech, S. G., Simó‐Servat, O., & Simó, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111841 · Cited by 43
“We also found that other cytokines such as IL-8 and MCP-1 were strikingly higher in vitreous fluid than in serum of patients with PDR [30].”
BackgroundInfluentialElsherbiny, N. M., Abdel–Mottaleb, Y., Elkazaz, A. Y., Atef, H., Lashine, R. M., Youssef, A. M., Morsy, W. E., El-Ghaiesh, S. H., Elshaer, R. E., El‐Shafey, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01089 · Cited by 44
“Most research assumes that neurodegeneration in the retina takes place secondarily to microvascular damage, however a growing body of evidence shows that neuroretinal alterations precede the vascular changes, and exist although clinically detectable retinal vasculopathy is absent (Yau et al., 2012; Rao et al., 2015).”
BackgroundLiu, F., SAUL, A. B., Pichavaram, P., Xu, Z., Rudraraju, M., Somanath, P. R., Smith, S. B., Caldwell, R. B., & Narayanan, S. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020340 · Cited by 43
Sarao, V., Veritti, D., & Lanzetta, P. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04853-y · Cited by 45
“2% of them having sight-threatening DR [1].”
Deep learning‐based detection and stage grading for optimising diagnosis of diabetic retinopathy
Wang, Y., Yu, M., Hu, B., Jin, X., Li, Y., Zhang, X., Zhang, Y., Gong, D., Wu, C., Zhang, B., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3445 · Cited by 43
Self-citationKatulanda, P., Ranasinghe, P. D., & Jayawardena, R. (2014) · BMC Ophthalmology · doi:10.1186/1471-2415-14-100 · Cited by 43
“Namperumalsamy P, Kim R, Vignesh TP, Nithya N, Royes J, Gijo T, Thulasiraj RD, Vijayakumar V: Prevalence and risk factors for diabetic retinopathy: a population-based assessment from Theni District, south India.”
BackgroundInfluentialGong, X., & Rubin, L. P. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.02.004 · Cited by 43
Trento, M., Passera, P., Trevisan, M., Schellino, F., Sitia, E., Albani, S., Montanaro, M., Bandello, F. M., Scoccianti, L., Charrier, L., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0470-1 · Cited by 43
“Diabetic retinopathy (DR) develops in most people with diabetes and may progress to sight-threatening stages in some of them [1].”
BackgroundSelf-citationCarelli, M., Maguolo, A., Zusi, C., Olivieri, F., Emiliani, F., Grandi, G. D., Unali, I., Zerman, N., Signoretto, C., & Maffeis, C. (2023) · Microorganisms · doi:10.3390/microorganisms11030668 · Cited by 46
Simó, R., Franch‐Nadal, J., Vlacho, B., Real, J., Amado, E., Roux, J. A. F., Mata‐Cases, M., Ortega, E., Rigla, M., Vallés, J.-A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2521 · Cited by 42
Peng, D., Wang, J., Zhang, R., Jiang, F., Tang, S., Chen, M., Yan, J. Y., Sun, X., Wang, S., Wang, T., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3569-9 · Cited by 42
Self-citationOptical Coherence Tomography Angiography of Diabetic Retinopathy
Bandello, F. M., Corbelli, E., Carnevali, A., Pierro, L., & Querques, G. (2016) · Developments in ophthalmology · doi:10.1159/000442801 · Cited by 42
Rasheed, R. A., & Adel, F. A. (2017) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2017.01.001 · Cited by 47
Zhang, Y., Qu, Y., Niu, T., Wang, H., & Liu, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.068 · Cited by 42
Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms
Hernández, C., Simó-Servat, A., Bogdanov, P. M., & Simó, R. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0648-4 · Cited by 42
Sengupta, S., Sindal, M. D., Besirli, C. G., Upadhyaya, S., Venkatesh, R., Niziol, L. M., Robin, A. L., Woodward, M. A., & Newman-Casey, P. A. (2017) · Eye · doi:10.1038/eye.2017.199 · Cited by 42
Analysis of Changes in Retinal Thickness in Type 2 Diabetes without Diabetic Retinopathy
Jiang, J., Liu, Y., Chen, Y., Ma, B., Qian, Y., Zhang, Z., Zhu, D., Wang, Z., & Xu, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3082893 · Cited by 42
“HbA1c levels predict the incidence and progression of DR [24].”
BackgroundFor the Japan Diabetes Complication and its Prevention prospective (JDCP) study Diabetic Retinopathy working group, Kawasaki, R., Kitano, S., Sato, Y., Yamashita, H., Nishimura, R., & Tajima, N. (2018) · Diabetology International · doi:10.1007/s13340-018-0357-z · Cited by 44
Self-citationChen, T., Zhu, W., Tang, B., Jin, L., Fu, H., Chen, Y., Wang, C., Zhang, G., Wang, J., Ye, T., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.006 · Cited by 42
“DR is currently the leading cause of blindness in the working age population world-wide,(7) and it is estimated that approximately one third of persons living with diabetes will have DR at any given time.(8) Vision impairment from this cause may lead to a loss of livelihood affecting not only workers, but also the fam…”
BackgroundSelf-citationFeasibility of Diagnosing Both Severity and Features of Diabetic Retinopathy in Fundus Photography
Wang, J., Bai, Y., & Xia, B. (2019) · IEEE Access · doi:10.1109/access.2019.2930941 · Cited by 44
Self-citationDaCosta, J., Bhatia, D., & Talks, J. S. (2019) · Eye · doi:10.1038/s41433-019-0606-9 · Cited by 42
“Globally, it has been estimated that diabetic macular oedema (DMO) affects ~23% of people with DR [2].”
BackgroundBen, Â. J., Neyeloff, J. L., de Souza, C. F., Rosses, A. P. O., de Araujo, A. L., Szortika, A., Locatelli, F., de Carvalho, G., & Neumann, C. R. (2020) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00528-w · Cited by 36
“The prevalence of DR among people with diabetes mellitus is around 35% worldwide [1, 3].”
BackgroundSantos, L. R. B., & Fleming, I. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106407 · Cited by 47
Relationship between diabetic macular edema and choroidal layer thickness
Endo, H., Kase, S., Takahashi, M., Saito, M., Yokoi, M., Sugawara, C., Katsuta, S., Ishida, S., & Kase, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226630 · Cited by 42
“Large-scale epidemiological studies indicated that elevated HbA1c increased the risk of the onset of DME [31,32].”
BackgroundYou, Q. S., Wang, J., Guo, Y., Pi, S., Flaxel, C. J., Bailey, S. T., Huang, D., Jia, Y., & Hwang, T. S. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.04.024 · Cited by 42
Self-citationPPARα Agonist Oral Therapy in Diabetic Retinopathy
Tomita, Y., Lee, D., Tsubota, K., & Kurihara, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100433 · Cited by 47
“As DR is the leading cause of blindness in industrialized countries [13], many researchers have tried to develop treatments for DR.”
BackgroundFive-Year Patterns of Diabetic Retinopathy Progression in US Clinical Practice
Moshfeghi, A. A., Garmo, V., Sheinson, D. M., Ghanekar, A., & Abbass, I. M. (2020) · Clinical ophthalmology · doi:10.2147/opth.s275968 · Cited by 43
Kumar, S., Kumar, G., Velu, S., Pardhan, S., Sivaprasad, S., Ruamviboonsuk, P., & Raman, R. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037277 · Cited by 47
Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review
Oddone, F., Rossetti, L. M., Parravano, M., Sbardella, D., Coletta, M., Ziccardi, L., Roberti, G., Carnevale, C., Romano, D., Manni, G., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14030281 · Cited by 45
“DR represents one of the most important complications of diabetes and preventable causes of visual impairment among people of working age and industrialized countries [103,104].”
Saucedo, L., Pfister, I. B., Zandi, S., Gerhardt, C., & Garweg, J. G. (2021) · Mediators of Inflammation · doi:10.1155/2021/9811361 · Cited by 45
“The most relevant factors associated with the prevalence and progression of DR are duration of diabetes, glycemic control, and hypertension [3, 4].”
Support vector machine and deep-learning object detection for localisation of hard exudates
Kurilová, V., Goga, J., Oravec, M., Pavlovičová, J., & Kajan, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-95519-0 · Cited by 45
Epigenetic Mechanisms of the Aging Human Retina
Pennington, K. L., & DeAngelis, M. M. (2015) · Journal of Experimental Neuroscience · doi:10.4137/jen.s25513 · Cited by 49
Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
Bravo‐Osuna, I., Andrés‐Guerrero, V., Arranz-Romera, A., Esteban-Pérez, S., Molina-Martínez, I. T., & Herrero‐Vanrell, R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.007 · Cited by 43
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes
Thomas, M. C. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154961 · Cited by 41
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Barriers and facilitators to diabetic retinopathy screening within Australian primary care
Watson, M. J. G., McCluskey, P., Grigg, J., Kanagasingam, Y., Daire, J., & Estai, M. (2021) · BMC Family Practice · doi:10.1186/s12875-021-01586-7 · Cited by 46
“According to Australia’s Eye Health Survey 2016, among adults 40 years of age and older, the sampling weight-adjusted prevalence of any DR and vision-threatening diabetic retinopathy (VTDR) was 39.4% (95% CI, 33.1–46.1) and 9.5% (95% CI, 6.8–13.1), respectively [3].”
BackgroundInfluentialPerspectives of diabetic retinopathy—challenges and opportunities
Sivaprasad, S., Sen, S., & Cunha-Vaz, J. G. (2022) · Eye · doi:10.1038/s41433-022-02335-5 · Cited by 44
“Retinal imaging for DR Colour fundus photography: The ETDRS group classified eyes with DR as mild, moderate, severe, very severe NPDR and early and high-risk PDR [1, 35, 36].”
BackgroundMethodInfluentialHwang, J., Rudnisky, C. J., Bowen, S., & Johnson, J. A. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.11.014 · Cited by 41
Adelman, R. A., Parnes, A. J., Michalewska, Z., Parolini, B., Boscher, C., & Ducournau, D. H. (2015) · BioMed Research International · doi:10.1155/2015/352487 · Cited by 41
“A metaanalysis extrapolated to the world diabetes population in 2010 estimated that approximately 93 million people may have some form of diabetic retinopathy (DR), and 28 million may have sight-threatening stages of DR [2].”
Arichika, S., Uji, A., Murakami, T., Unoki, N., Yoshitake, S., Dodo, Y., Ooto, S., Miyamoto, K., & Yoshimura, N. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15121 · Cited by 39
de Moraes, G., & Layton, C. J. (2016) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12795 · Cited by 43
“Diabetic retinopathy (DR) is a significant public health issue in all countries, with a 2011 estimate of 93 million sufferers worldwide.(1) The disease is the third most prevalent cause of visual impairment in the world,(2) and as the leading cause of vision loss in adults on working-age(1) it has a significant econom…”
BackgroundChen, H., Zhang, X., Liao, N., & Wen, F. (2016) · PubMed Central · Cited by 47
Self-citationDavila, J. R., Sengupta, S., Niziol, L. M., Sindal, M. D., Besirli, C. G., Upadhyaya, S., Woodward, M. A., Venkatesh, R., Robin, A. L., Grubbs, J., et al. (2017) · Ophthalmologica · doi:10.1159/000475773 · Cited by 43
López, M., Cos, X., Guisasola, F. Á., & Fuster, E. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2017.07.004 · Cited by 41
“with a detailed literature search evaluated the global DR prevalence and found rates of 35% [8] and 28% [9], respectively.”
BackgroundRecent advances in the management of diabetic retinopathy
Dulull, N. K., Kwa, F. A. A., Osman, N., Rai, U., Shaikh, B. H., & Thrimawithana, T. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.028 · Cited by 43
Jiao, W., Ji, J., Xu, W., Bu, W., Zheng, Y., Ma, A., Zhao, B., & Fan, Q. (2019) · Scientific Reports · doi:10.1038/s41598-019-51603-0 · Cited by 41
Imamura, M., Takahashi, A., Matsunami, M., Horikoshi, M., Iwata, M., Araki, S.-I., Toyoda, M., Susarla, G., Ahn, J., Park, K. H., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab044 · Cited by 44
“Its prevalence has been reported to be approximately 35% of patients with diabetes mellitus (1).”
BackgroundYao, L., Wang, X., Zhong, Y., Wang, Y., Wu, J., Geng, J., Zhou, Y., Chen, J., Guan, P., Xu, Y., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294408 · Cited by 41
“The homogeneity, pattern, and intensity of these factors vary considerably.(4) Currently, screening and diagnosis of DR depends on retina photography, and there is no exact detectable biomarker to predict the existence of DR.”
BackgroundNuclear factor of activated T-cells (NFAT) regulation of IL-1β-induced retinal vascular inflammation
Giblin, M. J., Smith, T. E., Winkler, G. A., Pendergrass, H. A., Kim, M. J., Capozzi, M. E., Yang, R., McCollum, G. W., & Penn, J. S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166238 · Cited by 42
Using artificial intelligence for diabetic retinopathy screening: Policy implications
Raman, R., Dasgupta, D., Ramasamy, K., George, R. J., Mohan, V., & Ting, D. S. W. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1420_21 · Cited by 46
Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature
van Hulten, V., Rasmussen, N. H., Driessen, J. H. M., Burden, A. M., Kvist, A. V., & van den Bergh, J. P. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00715-6 · Cited by 41
The prevalence of retinopathy in prediabetes: A systematic review
Kirthi, V., Nderitu, P., Alam, U., Evans, J. R., Nevitt, S. J., Malik, R. A., Hopkins, D., & Jackson, T. L. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.04.002 · Cited by 45
Diabetes-Related Microvascular Complications – A Practical Approach
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.008 · Cited by 43
Elafros, M. A., Callaghan, B. C., Skolarus, L. E., Vileikytė, L., Lawrenson, J. G., & Feldman, E. L. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09754-5 · Cited by 44
“, elevated HbA1c and fasting blood glucose, is a significant risk factor for developing microvascular complications, including retinopathy, nephropathy [34], and neuropathy [3].”
BackgroundRoig-Revert, M. J., Lleó-Pérez, A., Zanón‐Moreno, V., Vivar-Llopis, B., Marín-Montiel, J., Dolz‐Marco, R., Muñoz, L. A., Albert-Fort, M., Gálvez, M. I. L., Galarreta, D., et al. (2015) · BioMed Research International · doi:10.1155/2015/408180 · Cited by 43
“In this framework, it is well acknowledged that DR appearmore frequently in T1DM than in T2DM patients and that DR prevalence end points positively correlate with the length of time afflicted byDM, as well as by the glycosilated hemoglobin (HbA1c), and hypertension blood pressure (HBP) levels [11, 12].”
BackgroundGhodasra, D. H., Fante, R. J., Gardner, T. W., Langue, M. A., Niziol, L. M., Besirli, C. G., Cohen, S. R., Dedania, V. S., Demirci, H., Jain, N., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18721 · Cited by 41
“Diabetic retinopathy is a common complication occurring in approximately 35% of patients with diabetes.(1) Vision loss from diabetic retinopathy primarily occurs from either diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR).”
BackgroundBromfenac Eyedrops in the Treatment of Diabetic Macular Edema: A Pilot Study
Pinna, A., Blasetti, F., Ricci, G. D., & Boscia, F. (2016) · European Journal of Ophthalmology · doi:10.5301/ejo.5000888 · Cited by 41
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.